You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Venclexta

Showing 26 - 50 of 183
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Leukemia, Myeloid, Acute Trial (Cytarabine, Venetoclax, CPX-351)

Not yet recruiting
  • Leukemia, Myeloid, Acute
  • (no location specified)
Nov 25, 2022

Diffuse Large B Cell Lymphoma, Relapsed DLBCL, Refractory DLBCL Trial in Boston (Copanlisib, Venetoclax)

Active, not recruiting
  • Diffuse Large B Cell Lymphoma
  • +2 more
  • Duarte, California
  • +2 more
Nov 10, 2022

Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in

Not yet recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 10, 2023

AL Amyloidosis, Light Chain (AL) Amyloidosis, Systemic Light Chain Disease Trial in San Francisco (Venetoclax, Dexamethasone,

Not yet recruiting
  • AL Amyloidosis
  • +2 more
  • San Francisco, California
    University of California, San Francisco
Aug 16, 2022

CCND1 Positive, Mantle Cell Lymphoma, t(11;14) Positive Trial in Atlanta, Johns Creek (Bendamustine, Obinutuzumab, Venetoclax)

Active, not recruiting
  • CCND1 Positive
  • +2 more
  • Atlanta, Georgia
  • +2 more
Nov 2, 2022

Waldenstrom Macroglobulinemia, MYD88 Gene Mutation Trial in Boston (IBRUTINIB, Venetoclax)

Active, not recruiting
  • Waldenstrom Macroglobulinemia
  • MYD88 Gene Mutation
  • Boston, Massachusetts
  • +1 more
Apr 1, 2022

Secondary Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome Trial in Columbus (Azacitidine, Quality-of-Life

Recruiting
  • Secondary Myelodysplastic Syndrome
  • Therapy-Related Myelodysplastic Syndrome
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Dec 1, 2022

Follicular Lymphoma Trial in Chicago (Venetoclax, Obinutuzumab, CC-486)

Recruiting
  • Follicular Lymphoma
  • Chicago, Illinois
    University of Chicago Medical Center
Nov 12, 2021

Acute Myeloid Leukemia in Remission, FLT3 Gene Mutation, Hematologic and Lymphocytic Disorder Trial in Houston (Azacitidine,

Recruiting
  • Acute Myeloid Leukemia in Remission
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 13, 2022

AML, Adult, Chemo Effect Trial in Suzhou (Venetoclax, Decitabine for Injection, Cytarabine)

Recruiting
  • AML, Adult
  • Chemotherapy Effect
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University, Jiangsu Ins
Feb 28, 2022

Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Houston

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 12, 2022

Chronic Lymphocytic Leukemia (CLL) Trial in United States (Venetoclax, Obinutuzumab, Acalabrutinib)

Active, not recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Stamford, Connecticut
  • +4 more
Dec 2, 2022

Myeloid Malignancy, MDS, Myelofibrosis Trial in Boston (Navitoclax, Venetoclax, Decitabine)

Recruiting
  • Myeloid Malignancy
  • +4 more
  • Boston, Massachusetts
  • +2 more
Jul 21, 2022

Acute Myeloid Leukemia (AML) in Remission Trial in Suzhou (Azacitidine, Venetoclax, Supportive care)

Recruiting
  • Acute Myeloid Leukemia (AML) in Remission
  • Suzhou, Jiangsu, China
  • +1 more
Aug 18, 2022

Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Duarte (8-Chloroadenosine,

Recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Aug 15, 2022

Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia Trial in Houston (Decitabine, Quizartinib,

Recruiting
  • Acute Myeloid Leukemia
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 27, 2023

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Atlanta (Tocilizumab, Venetoclax)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Jan 24, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Columbus (Acalabrutinib, Obinutuzumab, Venetoclax)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Nov 2, 2022

Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma Trial in Boston (Venetoclax, Zanubrutinib)

Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma
  • Boston, Massachusetts
  • +2 more
Mar 16, 2022

Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive Trial in Houston (Acalabrutinib, Venetoclax)

Recruiting
  • Blastoid Variant Mantle Cell Lymphoma
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Acute Myeloid Leukemia Trial in Sacramento (Azacitidine, Uproleselan, Venetoclax)

Recruiting
  • Acute Myeloid Leukemia
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Aug 12, 2022

CLL Trial in Stony Brook, Oklahoma City (Zandelisib, Rituximab, Venetoclax)

Recruiting
  • CLL
  • Stony Brook, New York
  • +1 more
May 12, 2022

Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma Trial in Rochester (Acalabrutinib, Durvalumab,

Recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 4, 2023

Adverse Events and Change in Disease Activity in Participants

Recruiting
  • Acute Myeloid Leukemia (AML)
    • Seoul, Seoul Teugbyeolsi, Korea, Republic of
    • +5 more
    Nov 4, 2022

    Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma Trial in Chicago, Rochester, Cleveland (Venetoclax, Umbralisib, Ublituximab)

    Terminated
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Chicago, Illinois
    • +2 more
    Aug 19, 2022